复旦学报（医学版）
複旦學報（醫學版）
복단학보（의학판）
FUDAN UNIVERSITY JOURNAL OF MEDICAL SCIENCES
2009年
6期
696-700
,共5页
郑惠如%金美玲%任涛%张镭%储以微
鄭惠如%金美玲%任濤%張鐳%儲以微
정혜여%금미령%임도%장뢰%저이미
非小细胞肺癌%外周血单核细胞%调节性T细胞%IFN-γ%IL-12
非小細胞肺癌%外週血單覈細胞%調節性T細胞%IFN-γ%IL-12
비소세포폐암%외주혈단핵세포%조절성T세포%IFN-γ%IL-12
non-small cell lung cancer%peripheral bolld mononuclear cell%regulatory T cell%IFN-γ%IL-12
目的 比较非小细胞肺癌(non-small cell lung cancer,NSCLC)患者外周血CD3~+T细胞、CD4~+CD25~(high)调节性T细胞(regulatory T cell,Treg cell)、γ-干扰素(interferon γ,IFN-γ)和白介素-12(interleukin-12,IL-12)与健康人的差异,并分析化疗前后CD4~+CD25~(high)Treg细胞、IFN-γ和IL-12的改变,探讨肺癌患者化疗前后免疫功能的改变.方法 选取NSCLC患者20例,健康志愿者20例为对照.分别抽取患者化疗前、化疗后3 d及7 d外周血3 mL,分离其外周血单个核细胞 (peripheral blood mononuclear cell,PBMC),以流式细胞仪检测CD3~+T细胞比例、CD4~+CD25~(high)Treg细胞比例(%),并取上清液检测IFN-γ和IL-12.结果 健康组CD3~+T细胞比例为(61.52±13.46)%,肺癌组化疗前CD3~+T细胞比例为(55.15±20.11)%,化疗后3 d、7 d分别为(57.73±14.08)%和(62.79±7.80)%.肺癌组化疗前与化疗后3 d、7 d比较,差异无统计学意义(P>0.05).健康组CD4~+CD25~(high)Treg细胞的比例为(2.14±0.85)%;肺癌组CD4~+CD25~(high)Treg细胞的比例在化疗前为(2.76±0.53)%,较健康人明显升高(P<0.05);肺癌组CD4~+CD25~(high)Treg细胞的比例在化疗后3 d、7 d分别为(2.54±0.57)%、(2.72±0.29)%,较化疗前减少,而在3 d减少较7 d明显,各组比较,P<0.05.健康组 IFN-γ和IL-12分别为(34.36±4.38)和(33.24±4.36)pg/mL;肺癌组IFN-γ和IL-12在化疗前分别为(38.47±5.04)和(34.82±5.30)pg/mL,与健康组比较,差异无统计学意义(P>0.05).肺癌组IFN-γ在化疗后3 d、7 d分别为(40.42±5.66)和(39.27±6.07)pg/mL,较化疗前有所增加,化疗后3 d和化疗前比较,P<0.05,但化疗后7 d和化疗前比较,P>0.05.肺癌组IL-12在化疗后3 d、7 d分别为(35.51±5.03)和(38.62±6.44)pg/mL,较化疗前有所增加,化疗后3 d和化疗前比较,P>0.05,化疗后7 d和化疗前比较,P<0.05.结论 化疗对肺癌患者机体的免疫环境可能具有优化作用,从而增强机体的抗肿瘤免疫应答.
目的 比較非小細胞肺癌(non-small cell lung cancer,NSCLC)患者外週血CD3~+T細胞、CD4~+CD25~(high)調節性T細胞(regulatory T cell,Treg cell)、γ-榦擾素(interferon γ,IFN-γ)和白介素-12(interleukin-12,IL-12)與健康人的差異,併分析化療前後CD4~+CD25~(high)Treg細胞、IFN-γ和IL-12的改變,探討肺癌患者化療前後免疫功能的改變.方法 選取NSCLC患者20例,健康誌願者20例為對照.分彆抽取患者化療前、化療後3 d及7 d外週血3 mL,分離其外週血單箇覈細胞 (peripheral blood mononuclear cell,PBMC),以流式細胞儀檢測CD3~+T細胞比例、CD4~+CD25~(high)Treg細胞比例(%),併取上清液檢測IFN-γ和IL-12.結果 健康組CD3~+T細胞比例為(61.52±13.46)%,肺癌組化療前CD3~+T細胞比例為(55.15±20.11)%,化療後3 d、7 d分彆為(57.73±14.08)%和(62.79±7.80)%.肺癌組化療前與化療後3 d、7 d比較,差異無統計學意義(P>0.05).健康組CD4~+CD25~(high)Treg細胞的比例為(2.14±0.85)%;肺癌組CD4~+CD25~(high)Treg細胞的比例在化療前為(2.76±0.53)%,較健康人明顯升高(P<0.05);肺癌組CD4~+CD25~(high)Treg細胞的比例在化療後3 d、7 d分彆為(2.54±0.57)%、(2.72±0.29)%,較化療前減少,而在3 d減少較7 d明顯,各組比較,P<0.05.健康組 IFN-γ和IL-12分彆為(34.36±4.38)和(33.24±4.36)pg/mL;肺癌組IFN-γ和IL-12在化療前分彆為(38.47±5.04)和(34.82±5.30)pg/mL,與健康組比較,差異無統計學意義(P>0.05).肺癌組IFN-γ在化療後3 d、7 d分彆為(40.42±5.66)和(39.27±6.07)pg/mL,較化療前有所增加,化療後3 d和化療前比較,P<0.05,但化療後7 d和化療前比較,P>0.05.肺癌組IL-12在化療後3 d、7 d分彆為(35.51±5.03)和(38.62±6.44)pg/mL,較化療前有所增加,化療後3 d和化療前比較,P>0.05,化療後7 d和化療前比較,P<0.05.結論 化療對肺癌患者機體的免疫環境可能具有優化作用,從而增彊機體的抗腫瘤免疫應答.
목적 비교비소세포폐암(non-small cell lung cancer,NSCLC)환자외주혈CD3~+T세포、CD4~+CD25~(high)조절성T세포(regulatory T cell,Treg cell)、γ-간우소(interferon γ,IFN-γ)화백개소-12(interleukin-12,IL-12)여건강인적차이,병분석화료전후CD4~+CD25~(high)Treg세포、IFN-γ화IL-12적개변,탐토폐암환자화료전후면역공능적개변.방법 선취NSCLC환자20례,건강지원자20례위대조.분별추취환자화료전、화료후3 d급7 d외주혈3 mL,분리기외주혈단개핵세포 (peripheral blood mononuclear cell,PBMC),이류식세포의검측CD3~+T세포비례、CD4~+CD25~(high)Treg세포비례(%),병취상청액검측IFN-γ화IL-12.결과 건강조CD3~+T세포비례위(61.52±13.46)%,폐암조화료전CD3~+T세포비례위(55.15±20.11)%,화료후3 d、7 d분별위(57.73±14.08)%화(62.79±7.80)%.폐암조화료전여화료후3 d、7 d비교,차이무통계학의의(P>0.05).건강조CD4~+CD25~(high)Treg세포적비례위(2.14±0.85)%;폐암조CD4~+CD25~(high)Treg세포적비례재화료전위(2.76±0.53)%,교건강인명현승고(P<0.05);폐암조CD4~+CD25~(high)Treg세포적비례재화료후3 d、7 d분별위(2.54±0.57)%、(2.72±0.29)%,교화료전감소,이재3 d감소교7 d명현,각조비교,P<0.05.건강조 IFN-γ화IL-12분별위(34.36±4.38)화(33.24±4.36)pg/mL;폐암조IFN-γ화IL-12재화료전분별위(38.47±5.04)화(34.82±5.30)pg/mL,여건강조비교,차이무통계학의의(P>0.05).폐암조IFN-γ재화료후3 d、7 d분별위(40.42±5.66)화(39.27±6.07)pg/mL,교화료전유소증가,화료후3 d화화료전비교,P<0.05,단화료후7 d화화료전비교,P>0.05.폐암조IL-12재화료후3 d、7 d분별위(35.51±5.03)화(38.62±6.44)pg/mL,교화료전유소증가,화료후3 d화화료전비교,P>0.05,화료후7 d화화료전비교,P<0.05.결론 화료대폐암환자궤체적면역배경가능구유우화작용,종이증강궤체적항종류면역응답.
Objective To compare the proportion of CD3~+T cell and CD4~+CD25~(high) regulatory T cell (Treg cell) and the production of inferon γ ( IFN-γ) and interleukin-12 (IL-12) in peripheral blood mononuclear cells (PBMC) between patients with non-small cell lung cancer (NSCLC) and healthy people, and to analyze the changes of CD3~+T cell, CD4~+CD25~(high)Treg cell, IFN-γ and IL-12 of NSCLC patients before and after chemotherapy, so as to determine immune function changes of NSCLC patients caused by chemotherapy. Methods Twenty NSCLC patients and 20 healthy volunteers according to the including criteria were selected. Three mL of blood was drawn from NSCLC patients before chemotherapy (0 d), on the 3~(rd) day (3 d) and 7~(th) day (7 d) after chemotherapy. PBMC cells were separated from the blood samples. The proportions of CD4~+CD25~(high)Treg cell and CD3~+T cell (%) in PBMC were tested by FACS, and the IFN-γ and IL-12 (pg/mL) in the supernatants were also detected. Results The proportions of CD3~+T cell in NSCLC patients on 0, 3 and 7 d were (55.15±20.11)%,(57.73±14.08)% and (62.79±7.80)%,respectively, and there was no statistical difference between any two of these results. The proportion of CD4~+CD25~(high)Treg cell in healthy volunteers was (2.14±0.85)%, while that of NSCLC patients was (2.76±0.53)% on 0 d with statistical difference compared to the healthy volunteers (P<0.05). The CD4~+CD25~(high)Treg cell proportion (%) of NSCLC patients on 3 d and 7 d were (2.54±0.57)% and (2.72±0.29)%, respectively, which were both significantly lower than that of 0 d. On 3 d it was even much lower than that on 7 d (P<0.05). IFN-γ and IL-12 of NSCLC patients on 0 d were (34.36±4.38) pg/mL and (33.24±4.36) pg/mL, and no statistical difference was observed when compared with (34.36±4.38) pg/mL and (33.24±4.36) pg/mL in the healthy volunteers. On 3 d and 7 d, IFN-γ of NSCLC patients were (40.42±5.66) pg/mL and (39.27±6.07) pg/mL, respectively, and both were higher than that on 0 d (P<0.05); IL-12 of NSCLC patients were (35.51±5.03) pg/mL and (38.62±6.44) pg/mL, also both were higher than that on 0 d (P<0.05). Conclusions This study suggests that chemotherapy can improve immune functions of NSCLC patients, and may reinforce the anti-tumor immune response.
